文献速递妇产影像介入US

药物联合高强度聚焦超声治疗子宫腺肌病:随机对照试验的网状Meta分析

Combining Medication With High-Intensity-Focused Ultrasound for Adenomyosis: A Network Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Ultrasound Med · 2024-12-09

该网状Meta分析共纳入31篇随机对照试验,比较不同HIFU联合药物治疗子宫腺肌病的疗效。结果显示HIFU联合GnRH-a和孕激素在降低痛经VAS评分上优于其他联合方案,HIFU联合孕激素在缩小子宫体积、病灶大小和降低复发率上更优,HIFU联合米非司酮在减少月经量上更有效。

要点

  • HIFU联合GnRH-a和孕激素降低痛经VAS评分优于其他联合方案。
  • HIFU联合孕激素在缩小子宫体积、病灶大小及降低复发率方面更优。
  • HIFU联合米非司酮减少月经量效果优于其他联合方案。

核心结论

  • HIFU联合GnRH-a和孕激素、或HIFU联合孕激素、或HIFU联合米非司酮可能在子宫腺肌病临床管理中提供更优获益,这些联合方案可能对该病患者更有效。

研究设计与样本

  • 网状Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、CNKI、WanFang和VIP数据库至2024年2月21日,最终纳入31篇随机对照试验,结局包括痛经VAS评分、子宫体积、病灶体积、月经失血量及复发率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This network meta-analysis aims to identify the best possible combination therapy for individuals suffering from adenomyosis. To identify pertinent research for the network meta-analysis, a comprehensive search was conducted across multiple databases, including PubMed, Embase, Cochrane Library, Web of Science, CNKI, WanFang, and VIP, spanning from their commencement to February 21, 2024. The study's focus was on evaluating outcomes including visual analog scale (VAS) scores for dysmenorrhea, measurements of uterine and lesion volumes, menstrual blood loss, and the rate of disease recurrence. The findings from both direct and indirect comparisons, which were quantitatively assessed using weighted mean differences or relative risk along with their respective 95% confidence intervals, were graphically depicted in forest plots. Additionally, the ranking probability was illustrated, which indicated the likelihood of various high-intensity-focused ultrasound (HIFU) combination therapies being the most effective across each measured outcome. In the final analysis, this network meta-analysis encompassed a total of 31 articles. The results showed that HIFU combined with gonadotropin-releasing hormone agonist (GnRH-a) and progestin was more effective to decrease VAS score for dysmenorrhea than other combined therapies. HIFU combined with progestin was superior to other combined therapies in decreasing uterine volume, lesion size, and recurrence rate. HIFU combined with mifepristone was more effective to reduce menstrual volume compared to other combined therapies. The analysis suggests that regimens incorporating HIFU along with GnRH-a and progestin, or HIFU combined with progestin or HIFU combined with mifepristone might offer superior benefits in the clinical management of adenomyosis. These combined treatment approaches could potentially be more effective options for patients suffering from this condition.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Song Y, Wang L. Combining Medication With High-Intensity-Focused Ultrasound for Adenomyosis: A Network Meta-Analysis of Randomized Controlled Trials. J Ultrasound Med. 2024. PMID: 39648811. doi:10.1002/jum.16623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。